Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...

The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, ...

The company’s focus will be on progressing the clinical validation of its idiopathic pulmonary fibrosis treatment.

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, ...

The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...

Tech Mahindra and NVIDIA unveil an AI-powered pharmacovigilance solution to enhance drug safety, reducing delays, improving ...

Traditional methods of target identification in drug development often involve labor-intensive research and extensive experimental validation. This process can be time-consuming and fraught with ...

Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose ...

Insilico, which earns revenue from licensing assets in its pipeline to clients ... further develop its AI platform, and advance the clinical validation of its flagship drug candidate for ...

Chief executive Alex Zhavoronkov said the new round will "accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico's leadership in this rapidly evolving sector." ...